Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025

被引：0

作者：

Frutos, Aaron M. ^{[1
,2
]}

Cleary, Seana ^{[1
]}

Reeves, Emily L. ^{[1
]}

Ahmad, Haris M. ^{[1
]}

Price, Ashley M. ^{[1
]}

Self, Wesley H. ^{[3
]}

Zhu, Yuwei ^{[3
]}

Safdar, Basmah ^{[4
]}

Peltan, Ithan D. ^{[5
]}

Gibbs, Kevin W. ^{[6
]}

Exline, Matthew C. ^{[7
]}

Lauring, Adam S. ^{[8
]}

Ball, Sarah W. ^{[9
]}

Desilva, Malini ^{[10
]}

Tartof, Sara Y. ^{[11
]}

Dascomb, Kristin ^{[12
]}

Irving, Stephanie A. ^{[13
]}

Klein, Nicola P. ^{[14
]}

Dixon, Brian E. ^{[15
,16
]}

Ong, Toan C. ^{[17
]}

Vaughn, Ivana A. ^{[18
]}

House, Stacey L. ^{[19
]}

Faryar, Kiran A. ^{[20
]}

Nowalk, Mary Patricia ^{[21
]}

Gaglani, Manjusha ^{[22
,23
]}

Wernli, Karen J. ^{[24
,25
]}

Murugan, Vel ^{[26
]}

Williams, Olivia L. ^{[27
]}

Selvarangan, Rangaraj ^{[28
,29
]}

Weinberg, Geoffrey A. ^{[30
]}

Staat, Mary A. ^{[31
,32
]}

Halasa, Natasha B. ^{[3
]}

Sahni, Leila C. ^{[33
,34
]}

Michaels, Marian G. ^{[35
]}

Englund, Janet A. ^{[36
]}

Kirby, Marie K. ^{[1
]}

Surie, Diya ^{[37
]}

Dawood, Fatimah S. ^{[37
]}

Clopper, Benjamin R. ^{[37
]}

Moline, Heidi L. ^{[37
]}

Link-Gelles, Ruth ^{[37
]}

Payne, Amanda B.

Harker, Elizabeth ^{[1
]}

Wielgosz, Kristina ^{[1
]}

Weber, Zachary A. ^{[9
]}

Yang, Duck-Hye ^{[9
]}

Lewis, Nathaniel M. ^{[1
]}

Decuir, Jennifer ^{[1
]}

Olson, Samantha M. ^{[1
]}

Chung, Jessie R. ^{[1
]}

机构：

[1] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA

[2] CDC, Epidem Intelligence Serv, Geneva, Switzerland

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Yale Univ, New Haven, CT USA

[5] Intermt Med Ctr, Salt Lake City, UT USA

[6] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[7] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA

[8] Univ Michigan, Sch Med, Ann Arbor, MI USA

[9] Westat Corp, Clin Res Practice, Rockville, MD USA

[10] HealthPartners Inst, Minneapolis, MN USA

[11] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA

[12] Intermt Hlth, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA

[13] Kaiser Permanente Ctr Hlth Res, Sci Programs Dept, Portland, OR USA

[14] Kaiser Permanente Northern Calif Div Res, Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA

[15] Ctr Biomed Informat, Regenstrief Inst, Indianapolis, IN USA

[16] Indiana Univ, Fairbanks Sch Publ Hlth, Indianapolis, IN USA

[17] Univ Colorado, Dept Biomed Informat, Anschutz Med Campus, Aurora, CO USA

[18] Henry Ford Hlth, Dept Publ Hlth Sci, Detroit, MI USA

[19] Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO USA

[20] Univ Hosp Cleveland, Dept Emergency Med, Cleveland, OH USA

[21] Univ Pittsburgh, Dept Family Med, Pittsburgh, PA USA

[22] Baylor Scott & White Hlth, Dept Pediat, Temple, TX USA

[23] Baylor Coll Med, Dept Pediat, Temple, TX USA

[24] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[25] Kaiser Permanente Bernard J Tyson Sch Med, Pasadena, CA USA

[26] Arizona State Univ, Biodesign Ctr Personalized Diagnost, Tempe, AZ USA

[27] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA

[28] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA

[29] Childrens Mercy Hosp, Kansas City, MO USA

[30] Univ Rochester, Sch Med & Dent, Rochester, NY USA

[31] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA

[32] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[33] Texas Childrens Hosp, Houston, TX USA

[34] Baylor Coll Med, Houston, TX USA

[35] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA

[36] Seattle Childrens Res Inst, Seattle, WA USA

[37] CDC, Natl Ctr Immunizat & Resp Dis, Coronavirus & Other Resp Viruses Div, Atlanta, GA USA

来源：

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2025年 / 74卷 / 06期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Annual influenza vaccination is recommended for all persons aged >= 6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged <18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged >= 18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged >= 6 months as long as influenza viruses continue to circulate locally.

引用

页码：83 / 90

页数：8

共 8 条

[1] Influenza Vaccine Effectiveness: Defining the H3N2 Problem
Belongia, Edward A.
McLean, Huong Q.
[J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) : 1817 - 1823
[2] Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season
Chung, Jessie R.
Price, Ashley M.
Zimmerman, Richard K.
Geffel, Krissy Moehling
House, Stacey L.
Curley, Tara
Wernli, Karen J.
Phillips, C. Hallie
Martin, Emily T.
Vaughn, Ivana A.
Murugan, Vel
Scotch, Matthew
Saade, Elie A.
Faryar, Kiran A.
Gaglani, Manjusha
Ramm, Jason D.
Williams, Olivia L.
Walter, Emmanuel B.
Kirby, Marie K.
Keong, Lisa M.
Kondor, Rebecca
Ellington, Sascha R.
Flannery, Brendan
US Flu VE Network Investigators
[J]. CLINICAL INFECTIOUS DISEASES, 2025,
[3] Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors
Doll, Margaret K.
Pettigrew, Stacy M.
Ma, Julia
Verma, Aman
[J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E564 - E571
[4] Frutos AM, 2024, MMWR-MORBID MORTAL W, V73, P168, DOI 10.15585/mmwr.mm7308a3
[5] Grohskopf LA, 2024, MMWR RECOMM REP, V73, P1, DOI 10.15585/mmwr.rr7305a1
[6] Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020
Rose, Angela
Kissling, Esther
Emborg, Hanne-Dorthe
Larrauri, Amparo
McMenamin, Jim
Pozo, Francisco
Trebbien, Ramona
Mazagatos, Clara
Whitaker, Heather
Valenciano, Marta
[J]. EUROSURVEILLANCE, 2020, 25 (10) : 16 - 29
[7] Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25
Separovic, Lea
Zhan, Yuping
Kaweski, Samantha E.
Sabaiduc, Suzana
Carazo, Sara
Olsha, Romy
Mather, Richard G.
Dickinson, James A.
Hasso, Maan
Meunier, Isabelle
Jassem, Agatha N.
Zelyas, Nathan
Gaol, Ruimin
Bastien, Nathalie
Skowronski, Danuta M.
[J]. EUROSURVEILLANCE, 2025, 30 (04)
[8] Zeno EE, 2024, MMWR-MORBID MORTAL W, V73, P861, DOI 10.15585/mmwr.mm7339a1

← 1 →